saw palmetto berry and Reduced Lower Urinary Tract Symptom

Doses used in studies

mg/day: 320 (median 320, IQR 320–320) — 1 study

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

potassium changeIncreased risk
potassium (p=0.03)
from: A detailed safety assessment of a saw palmetto extract.
total bilirubin changeIncreased riskp=0.001
only small differences observed in changes over time in total bilirubin (p=0.001)
from: A detailed safety assessment of a saw palmetto extract.
total bilirubin increaseIncreased risk
with only small differences observed in changes over time in total bilirubin (p=0.001)
from: A detailed safety assessment of a saw palmetto extract.
_overall non-serious symptomatic adverse eventsNo significant difference34.8% vs. 30.1%, p=0.48
There were no significant differences observed between the saw palmetto and placebo-allocated participants in the risk of suffering at least one serious adverse event (5.4% vs. 9.7%, respectively; p=0.31) or non-serious symptomatic adverse event (34.8% vs. 30.1%, p=0.48)
from: A detailed safety assessment of a saw palmetto extract.
_overall serious adverse eventsNo significant differenceSerious adverse event5.4% vs. 9.7%, respectively; p=0.31
There were no significant differences observed between the saw palmetto and placebo-allocated participants in the risk of suffering at least one serious adverse event (5.4% vs. 9.7%, respectively; p=0.31)
from: A detailed safety assessment of a saw palmetto extract.
_overall sexual functioningNo significant difference
There were few significant between-group differences in sexual functioning
from: A detailed safety assessment of a saw palmetto extract.
changes in sexual functioningNo significant difference
There were few significant between-group differences in sexual functioning
from: A detailed safety assessment of a saw palmetto extract.
non-serious symptomatic adverse eventsNo significant difference34.8% vs. 30.1%
or non-serious symptomatic adverse event (34.8% vs. 30.1%, p=0.48)
from: A detailed safety assessment of a saw palmetto extract.
serious adverse eventsNo significant differenceSerious adverse event5.4% vs. 9.7%
There were no significant differences observed between the saw palmetto and placebo-allocated participants in the risk of suffering at least one serious adverse event (5.4% vs. 9.7%, respectively; p=0.31)
from: A detailed safety assessment of a saw palmetto extract.
glycosuriaReported0% in the saw palmetto group vs. 3.7% in the placebo group
the incidence of glycosuria (0% in the saw palmetto group vs. 3.7% in the placebo group, p=0.05)
from: A detailed safety assessment of a saw palmetto extract.

1 of 1 paper

A detailed safety assessment of a saw palmetto extract.
- 2008-06
- RCT · n = 225
- Complementary therapies in medicine 16(3)
- - Andrew L Avins
  - Stephen Bent
  - Suzanne Staccone
  - Evelyn Badua
  - Amy Padula
  - Harley Goldberg
  - John Neuhaus
  - Esther Hudes
  - Katusto Shinohara
  - Christopher Kane
- PubMed: 18534327
- DOI: 10.1016/j.ctim.2007.10.005
5 Insights on
- Reduced Lower Urinary Tract Symptom
- High evidence
- Large Human Trial
- Clinical
There were no significant differences observed between the saw palmetto and placebo-allocated participants in the risk of suffering at least one serious adverse event (5.4% vs. 9.7%, respectively; p=0.31) or non-serious symptomatic adverse event (34.8% vs. 30.1%, p=0.48).
Effect
Neutral
Effect size
Small
Significant
No
Dose
160 mg twice daily

saw palmetto berry and Reduced Lower Urinary Tract Symptom

A detailed safety assessment of a saw palmetto extract.